vs
AtriCure, Inc.（ATRC）与Rapid7, Inc.（RPD）财务数据对比。点击上方公司名可切换其他公司
Rapid7, Inc.的季度营收约是AtriCure, Inc.的1.5倍（$217.4M vs $140.5M），AtriCure, Inc.同比增速更快（13.1% vs 0.5%），Rapid7, Inc.自由现金流更多（$36.4M vs $18.4M），过去两年AtriCure, Inc.的营收复合增速更高（13.6% vs 3.0%）
AtriCure是一家专注于心房颤动及相关心脏病症治疗的医疗设备企业，研发并生产创新外科手术工具与疗法，主要服务北美、欧洲、亚太地区的医院、心脏外科中心及医疗机构，为微创心脏手术提供高效可靠的适配解决方案。
Rapid7是全球领先的网络安全企业，提供漏洞管理、威胁检测与响应、云安全、安全分析等全系列安全解决方案，服务全球科技、医疗、金融、制造等行业的各类规模企业及公共部门客户，助力客户高效识别、应对和缓解网络安全风险。
ATRC vs RPD — 直观对比
营收规模更大
RPD
是对方的1.5倍
$140.5M
营收增速更快
ATRC
高出12.5%
0.5%
自由现金流更多
RPD
多$18.0M
$18.4M
两年增速更快
ATRC
近两年复合增速
3.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $140.5M | $217.4M |
| 净利润 | — | $3.1M |
| 毛利率 | 75.0% | 68.9% |
| 营业利润率 | 1.8% | 1.0% |
| 净利率 | — | 1.4% |
| 营收同比 | 13.1% | 0.5% |
| 净利润同比 | — | 44.1% |
| 每股收益（稀释后） | $0.04 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATRCRPD
| Q4 25 | $140.5M | $217.4M | ||
| Q3 25 | $134.3M | $218.0M | ||
| Q2 25 | $136.1M | $214.2M | ||
| Q1 25 | $123.6M | $210.3M | ||
| Q4 24 | $124.3M | $216.3M | ||
| Q3 24 | $115.9M | $214.7M | ||
| Q2 24 | $116.3M | $208.0M | ||
| Q1 24 | $108.9M | $205.1M |
净利润ATRCRPD
| Q4 25 | — | $3.1M | ||
| Q3 25 | $-267.0K | $9.8M | ||
| Q2 25 | $-6.2M | $8.3M | ||
| Q1 25 | $-6.7M | $2.1M | ||
| Q4 24 | — | $2.2M | ||
| Q3 24 | $-7.9M | $15.4M | ||
| Q2 24 | $-8.0M | $6.5M | ||
| Q1 24 | $-13.3M | $1.4M |
毛利率ATRCRPD
| Q4 25 | 75.0% | 68.9% | ||
| Q3 25 | 75.5% | 70.2% | ||
| Q2 25 | 74.5% | 70.6% | ||
| Q1 25 | 74.9% | 71.7% | ||
| Q4 24 | 74.5% | 69.5% | ||
| Q3 24 | 74.9% | 70.6% | ||
| Q2 24 | 74.7% | 70.7% | ||
| Q1 24 | 74.7% | 70.3% |
营业利润率ATRCRPD
| Q4 25 | 1.8% | 1.0% | ||
| Q3 25 | 0.2% | 2.7% | ||
| Q2 25 | -4.5% | 1.6% | ||
| Q1 25 | -4.8% | -0.0% | ||
| Q4 24 | -11.7% | 3.4% | ||
| Q3 24 | -6.4% | 6.0% | ||
| Q2 24 | -6.2% | 2.5% | ||
| Q1 24 | -10.0% | 4.7% |
净利率ATRCRPD
| Q4 25 | — | 1.4% | ||
| Q3 25 | -0.2% | 4.5% | ||
| Q2 25 | -4.5% | 3.9% | ||
| Q1 25 | -5.5% | 1.0% | ||
| Q4 24 | — | 1.0% | ||
| Q3 24 | -6.8% | 7.2% | ||
| Q2 24 | -6.9% | 3.1% | ||
| Q1 24 | -12.2% | 0.7% |
每股收益（稀释后）ATRCRPD
| Q4 25 | $0.04 | $0.05 | ||
| Q3 25 | $-0.01 | $0.15 | ||
| Q2 25 | $-0.13 | $0.13 | ||
| Q1 25 | $-0.14 | $0.03 | ||
| Q4 24 | $-0.33 | $0.08 | ||
| Q3 24 | $-0.17 | $0.21 | ||
| Q2 24 | $-0.17 | $0.09 | ||
| Q1 24 | $-0.28 | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.4M | $474.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $491.9M | $154.7M |
| 总资产 | $654.2M | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ATRCRPD
| Q4 25 | $167.4M | $474.7M | ||
| Q3 25 | $147.9M | $407.1M | ||
| Q2 25 | $117.8M | $511.7M | ||
| Q1 25 | $99.9M | $493.5M | ||
| Q4 24 | $122.7M | $521.7M | ||
| Q3 24 | $130.3M | $443.7M | ||
| Q2 24 | $114.0M | $442.6M | ||
| Q1 24 | $106.0M | $411.7M |
总债务ATRCRPD
| Q4 25 | — | — | ||
| Q3 25 | $61.9M | — | ||
| Q2 25 | $61.9M | — | ||
| Q1 25 | $61.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $61.9M | — | ||
| Q2 24 | $61.9M | — | ||
| Q1 24 | $61.9M | — |
股东权益ATRCRPD
| Q4 25 | $491.9M | $154.7M | ||
| Q3 25 | $476.5M | $127.2M | ||
| Q2 25 | $464.5M | $90.4M | ||
| Q1 25 | $454.6M | $52.7M | ||
| Q4 24 | $461.0M | $17.7M | ||
| Q3 24 | $465.0M | $-5.1M | ||
| Q2 24 | $462.1M | $-52.6M | ||
| Q1 24 | $456.3M | $-86.4M |
总资产ATRCRPD
| Q4 25 | $654.2M | $1.7B | ||
| Q3 25 | $635.4M | $1.7B | ||
| Q2 25 | $608.8M | $1.6B | ||
| Q1 25 | $591.6M | $1.6B | ||
| Q4 24 | $609.3M | $1.7B | ||
| Q3 24 | $615.1M | $1.6B | ||
| Q2 24 | $597.3M | $1.5B | ||
| Q1 24 | $591.6M | $1.5B |
负债/权益比ATRCRPD
| Q4 25 | — | — | ||
| Q3 25 | 0.13× | — | ||
| Q2 25 | 0.13× | — | ||
| Q1 25 | 0.14× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $20.0M | $37.6M |
| 自由现金流经营现金流 - 资本支出 | $18.4M | $36.4M |
| 自由现金流率自由现金流/营收 | 13.1% | 16.8% |
| 资本支出强度资本支出/营收 | 1.1% | 0.5% |
| 现金转化率经营现金流/净利润 | — | 12.01× |
| 过去12个月自由现金流最近4个季度 | $48.3M | $146.2M |
8季度趋势，按日历期对齐
经营现金流ATRCRPD
| Q4 25 | $20.0M | $37.6M | ||
| Q3 25 | $26.7M | $39.0M | ||
| Q2 25 | $21.6M | $47.5M | ||
| Q1 25 | $-11.0M | $29.8M | ||
| Q4 24 | $5.8M | $63.8M | ||
| Q3 24 | $20.0M | $44.0M | ||
| Q2 24 | $7.4M | $32.9M | ||
| Q1 24 | $-21.0M | $31.1M |
自由现金流ATRCRPD
| Q4 25 | $18.4M | $36.4M | ||
| Q3 25 | $24.1M | $34.8M | ||
| Q2 25 | $19.0M | $46.6M | ||
| Q1 25 | $-13.2M | $28.4M | ||
| Q4 24 | $3.1M | $62.6M | ||
| Q3 24 | $16.4M | $42.6M | ||
| Q2 24 | $5.0M | $32.6M | ||
| Q1 24 | $-23.8M | $30.4M |
自由现金流率ATRCRPD
| Q4 25 | 13.1% | 16.8% | ||
| Q3 25 | 18.0% | 16.0% | ||
| Q2 25 | 13.9% | 21.8% | ||
| Q1 25 | -10.7% | 13.5% | ||
| Q4 24 | 2.5% | 28.9% | ||
| Q3 24 | 14.1% | 19.9% | ||
| Q2 24 | 4.3% | 15.7% | ||
| Q1 24 | -21.9% | 14.8% |
资本支出强度ATRCRPD
| Q4 25 | 1.1% | 0.5% | ||
| Q3 25 | 1.9% | 1.9% | ||
| Q2 25 | 2.0% | 0.4% | ||
| Q1 25 | 1.8% | 0.6% | ||
| Q4 24 | 2.2% | 0.5% | ||
| Q3 24 | 3.1% | 0.6% | ||
| Q2 24 | 2.1% | 0.1% | ||
| Q1 24 | 2.5% | 0.3% |
现金转化率ATRCRPD
| Q4 25 | — | 12.01× | ||
| Q3 25 | — | 3.97× | ||
| Q2 25 | — | 5.70× | ||
| Q1 25 | — | 14.14× | ||
| Q4 24 | — | 29.36× | ||
| Q3 24 | — | 2.85× | ||
| Q2 24 | — | 5.03× | ||
| Q1 24 | — | 22.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATRC
| Appendage Management | $45.5M | 32% |
| Openheart | $38.5M | 27% |
| Other | $26.2M | 19% |
| Pain Management | $22.6M | 16% |
| Minimally Invasive | $7.7M | 6% |
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
